EPA endocrine disruptors review
This article was originally published in The Rose Sheet
Executive Summary
Agency's Endocrine Disruptor Methods Validation Subcommittee will meet Dec. 10-12 in Washington, D.C. to discuss next steps involved with validating Pubertal and Aromatase assays and receive introductory presentation on Adult Intact Male assay. Group also will receive updates on the Androgen Receptor Binding assay, efforts to finalize reference chemicals, the OECD Fish Drafting Group and activities regarding in vitro fish assays. EPA was directed by the 1996 Food Quality Protection Act to develop a screening program to assess whether certain substances have hormonal effects in humans...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.